Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.341
-0.102 (-22.99%)
At close: Jun 26, 2026, 4:00 PM EDT
0.350
+0.009 (2.64%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.
The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Operating Officer, Chief Executive Officer and Director |
| Thomas G. Wiggans | Executive Chairman |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Herbert C. Cross CPA | Chief Financial Officer and Corporate Secretary |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 15, 2026 | ARS | Filing |
| Jun 15, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 15, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 9, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 8-K | Current Report |
| May 21, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | SCHEDULE 13G/A | Filing |